RYTHM (RYM) vs. Its Peers Financial Analysis
by Mitch Edgeman · The Markets DailyRYTHM (NASDAQ:RYM – Get Free Report) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare RYTHM to similar companies based on the strength of its analyst recommendations, valuation, institutional ownership, profitability, earnings, risk and dividends.
Volatility & Risk
RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s rivals have a beta of -3.17, indicating that their average stock price is 417% less volatile than the S&P 500.
Profitability
This table compares RYTHM and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RYTHM | -6.20% | -12.57% | -2.60% |
| RYTHM Competitors | -2,319.38% | -223.46% | -16.98% |
Institutional and Insider Ownership
6.0% of RYTHM shares are owned by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for RYTHM and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
| RYTHM Competitors | 7577 | 13642 | 25442 | 998 | 2.42 |
As a group, “Pharmaceuticals” companies have a potential upside of 29.84%. Given RYTHM’s rivals stronger consensus rating and higher possible upside, analysts clearly believe RYTHM has less favorable growth aspects than its rivals.
Valuation & Earnings
This table compares RYTHM and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| RYTHM | $51.01 million | -$33.26 million | -2.09 |
| RYTHM Competitors | $17.90 billion | $3.15 billion | 549.84 |
RYTHM’s rivals have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
RYTHM rivals beat RYTHM on 9 of the 13 factors compared.
About RYTHM
Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.